Volume 30, No 11, Nov 2020

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 30 Issue 11, November 2020: 942-943

RESEARCH HIGHLIGHTS

Inosine: novel microbiota-derived immunostimulatory metabolite

Guido Kroemer^1,2,3,4,5,* , Laurence Zitvogel^4,6,7,8,9

¹Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, Paris, France
²Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France
³Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
⁴Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, Jiangsu, China
⁵Karolinska Institute, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden
⁶Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France
⁷Gustave Roussy Comprehensive Cancer Institute, Villejuif, France
⁸INSERM, U1015 Villejuif, France
⁹Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Villejuif 1428, France
Correspondence: Guido Kroemer(Kroemer@orange.fr)

In a recent paper published in Science , Mager et al. identify inosine as a metabolite produced by Bifidobacterium pseudolongum that improves the efficacy of anticancer immunotherapy in mice. Inosine produced in the gut reaches adenosine A2A receptors of T lymphocytes infiltrating tumors; thus, inosine joins an expanding list of immunostimulatory metabolites produced in the gut.

https://doi.org/10.1038/s41422-020-00417-1

FULL TEXT | PDF

Browse 717